Preventing alcohol use in patients taking opioid medications
Co-Use of Opioid Medications and Alcohol Prevention Study (COAPS)
This study is testing a new program in community pharmacies to help patients who are using both alcohol and opioid medications reduce their alcohol use and stay healthier.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Utah Academic / other |
| Locations | 1 site (Nashville, Tennessee) |
| Trial ID | NCT05599672 on ClinicalTrials.gov |
What this trial studies
This study aims to address the co-use of alcohol and opioid medications, which poses significant health risks. It will adapt a previously developed intervention to test its acceptability, feasibility, and preliminary efficacy among community pharmacy patients. The intervention, known as Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM), will involve medication management combined with screening and brief intervention strategies. The study will be conducted in three community pharmacy locations, focusing on patients who are currently using alcohol and prescribed opioid medications.
Who should consider this trial
Good fit: Ideal candidates for this study are English-speaking adults aged 18 and older who are currently using alcohol and prescribed opioid medications.
Not a fit: Patients who are pregnant, receiving cancer treatment, or have experienced a recent psychotic or manic episode may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved safety and health outcomes for patients using opioids by reducing alcohol consumption.
How similar studies have performed: While there is limited literature on this specific intervention, previous studies have indicated a significant overlap between alcohol use disorders and opioid addiction, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * English speaking * ≥18 years * Not receiving cancer treatment * Current alcohol use * Prescribed an opioid medication Exclusion Criteria: * SA 2 exclusion * Are pregnant * Cannot provide collateral contact information for ≥2 persons * Do not have a reliable land line or mobile phone to be contacted by study staff * Are filling only buprenorphine * Plan to leave the area for an extended period of time in the next 3-months, or * Have experienced a psychotic and/or manic episode in the last 30 days
Where this trial is running
Nashville, Tennessee
- University of Tennessee College of Medicine — Nashville, Tennessee, United States (Recruiting)
Study contacts
- Study coordinator: Gerald Cochran, PhD
- Email: jerry.cochran@hsc.utah.edu
- Phone: 801-213-0654
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.